【已改】红线的地方有疑问rxr基础胰岛素联合DPP4抑制剂对2型糖尿病患者的临床研究.doc

红线的地方有疑问，推断有错误 基础胰岛素联合DPP-4抑制剂对2型糖尿病患者的临床研究 摘要:目的：探讨基础胰岛素联合DPP-4抑制剂在治疗2型糖尿病方面的临床疗效。方法：选择我院自2012年7月至2014年7月收治的80例2型糖尿病（FBS＞11.1mmol/L）患者，根据随机的原则，将患者分为治疗组40例与对照组40例，全部患者均给予生活方式干预，治疗组给予地特胰岛素联合西格列汀100mg，1天/次，餐前口服；对照组给予地特胰岛素联合瑞格那奈1mg，3次/d，三餐前口服治疗。结果：经治疗后，治疗组患者在空腹及餐后两小时血糖（PBG、2hPBG），HBA1C，血脂谱，体重指数（BMI）有明显下降，且具有统计学意义（P＜0.05），治疗组患者上述指标治疗后与对照组比较，结果具有显著性差异（P＜0.05）；两组患者治疗后，胰岛β功能均较治疗前均有明显下降，但治疗组改善情况更为明显，治疗组治疗后胰岛β??能均较对照组比较，结果具有显著性差异（P＜0.05），治疗期间观察组患者均未出现低血糖反应，未见其它临床不良反应，两组比较，无显著性差异（P0.05）。两组患者血糖达标率及血糖达标中位时间比较，结果具有显著性差异（P0.05）。结论：基础胰岛素联合DPP-4抑制剂在治疗2型糖尿病方面具有较好的临床疗效，且治疗安全性高，可临床推广应用。 关键词:2型糖尿病；DPP-4抑制剂；胰岛素 Basic insulin joint DPP-4 inhibitors in patients with type 2 diabetes clinical studies Abstract: Objective: To study the basic insulin joint DPP 4 inhibitors in the treatment of type 2 diabetes mellitus in the clinical curative effect.Methods: Our hospital from July 2012 to July 2014 were treated 80 cases of type 2 diabetes (FBS tendency 11.1 L) patients, based on the principle of random, divided the patients into the treatment group 40 cases and control group 40 cases, all patients were given lifestyle intervention, treatment group was given to insulin joint west Glenn dean 100 mg, 1 day/time, pre-dinner oral;The control group given to Craig that nai insulin joint treatment.Results: After treatment, the treatment group patients in the two hours fasting and postprandial blood glucose (PBG, 2 HPBG), HBA1C, blood lipid, body mass index (BMI) significantly lower earlier, with statistical significance (P 0.05), and compared with control group, the results have significant difference (P＜ 0.05);Two groups of patients were compared, islet beta function was significantly decreased, the but the treatment group improved more significantly (P 0.05), treatment group patients did not appear hypoglycemia, did not see other clinical adverse reactions, comparing the two groups, there was no significant difference (P 0.05). Two groups of patients with blood sugar